Alzheimer's disease (AD) is the most common cause of dementia with no cure at present. Cholesterol metabolism is closely associated with AD at several stages. ACAT1 converts free cholesterol to cholesteryl esters, and plays important roles in cellular cholesterol homeostasis. Recent studies show that in a mouse model, blocking ACAT1 provides multiple beneficial effects on AD. Here we review the current evidence that implicates ACAT1 as a therapeutic target for AD. We also discuss the potential usage of various ACAT inhibitors currently available to treat AD.
Yohei Shibuya, Catherine Cy Chang, Ta-Yuan Chang. ACAT1/SOAT1 as a therapeutic target for Alzheimer's disease. Future medicinal chemistry. 2015;7(18):2451-67
PMID: 26669800
View Full Text